ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has been given an average recommendation of “Hold” by the six research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $16.50.

A number of equities research analysts have recently commented on the company. HC Wainwright set a $10.00 price objective on ZIOPHARM Oncology and gave the company a “buy” rating in a research note on Tuesday, August 1st. ValuEngine upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, BidaskClub upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th.

ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/30/ziopharm-oncology-inc-ziop-receives-consensus-rating-of-hold-from-brokerages.html.

Several hedge funds and other institutional investors have recently modified their holdings of ZIOP. Amalgamated Bank grew its holdings in shares of ZIOPHARM Oncology by 12.9% during the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,924 shares in the last quarter. Mission Wealth Management LLC purchased a new position in shares of ZIOPHARM Oncology during the first quarter worth about $108,000. BB&T Securities LLC purchased a new position in shares of ZIOPHARM Oncology during the second quarter worth about $112,000. Oppenheimer & Co. Inc. grew its holdings in shares of ZIOPHARM Oncology by 50.0% during the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of ZIOPHARM Oncology by 7.5% during the second quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,673 shares in the last quarter. 41.94% of the stock is owned by institutional investors.

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at 6.14 on Friday. The company’s 50-day moving average is $5.85 and its 200 day moving average is $6.25. The firm’s market cap is $863.48 million. ZIOPHARM Oncology has a 1-year low of $4.84 and a 1-year high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. ZIOPHARM Oncology’s revenue was down 5.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.01) earnings per share. On average, equities research analysts expect that ZIOPHARM Oncology will post ($0.56) EPS for the current fiscal year.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.